Our studies on iron metabolism/ferroptosis show a significantly increased risk of relapse/resistance for a relatively small subset of AML patients having similarities in cellular iron metabolism when compared with normal CD34+ bone marrow cells. Here, CD34 is linked to acute myeloid leukemia.